- Home
- ATLC vs EYPT Comparison
ATLC vs EYPT Comparison
Compare ATLC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLC
- EYPT
- Stock Information
- Founded
- ATLC 1996
- EYPT 1987
- Country
- ATLC United States
- EYPT United States
- Employees
- ATLC N/A
- EYPT N/A
- Industry
- ATLC Finance: Consumer Services
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- ATLC Finance
- EYPT Industrials
- Exchange
- ATLC Nasdaq
- EYPT Nasdaq
- Market Cap
- ATLC 900.3M
- EYPT 741.0M
- IPO Year
- ATLC 1999
- EYPT 2005
- Fundamental
- Price
- ATLC $61.35
- EYPT $11.09
- Analyst Decision
- ATLC Buy
- EYPT Strong Buy
- Analyst Count
- ATLC 7
- EYPT 7
- Target Price
- ATLC $66.14
- EYPT $24.29
- AVG Volume (30 Days)
- ATLC 45.4K
- EYPT 643.4K
- Earning Date
- ATLC 08-07-2025
- EYPT 08-06-2025
- Dividend Yield
- ATLC N/A
- EYPT N/A
- EPS Growth
- ATLC 35.13
- EYPT N/A
- EPS
- ATLC 5.69
- EYPT N/A
- Revenue
- ATLC $457,158,000.00
- EYPT $51,898,000.00
- Revenue This Year
- ATLC $274.30
- EYPT N/A
- Revenue Next Year
- ATLC $12.69
- EYPT N/A
- P/E Ratio
- ATLC $10.78
- EYPT N/A
- Revenue Growth
- ATLC 26.20
- EYPT 2.99
- 52 Week Low
- ATLC $30.00
- EYPT $3.91
- 52 Week High
- ATLC $64.70
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- ATLC 70.20
- EYPT 61.85
- Support Level
- ATLC $49.05
- EYPT $10.22
- Resistance Level
- ATLC $62.86
- EYPT $11.28
- Average True Range (ATR)
- ATLC 2.28
- EYPT 0.71
- MACD
- ATLC 1.44
- EYPT 0.04
- Stochastic Oscillator
- ATLC 89.07
- EYPT 89.89
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.